Concepts (105)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 11 | 2024 | 2762 | 0.860 |
Why?
|
| Healthcare Disparities | 3 | 2024 | 479 | 0.440 |
Why?
|
| Ovarian Neoplasms | 3 | 2021 | 464 | 0.320 |
Why?
|
| Clinical Trials as Topic | 2 | 2024 | 1153 | 0.320 |
Why?
|
| Pancreatic Neoplasms | 3 | 2021 | 732 | 0.290 |
Why?
|
| Receptor, ErbB-2 | 4 | 2023 | 559 | 0.260 |
Why?
|
| Eligibility Determination | 1 | 2024 | 38 | 0.230 |
Why?
|
| Patient Selection | 2 | 2024 | 732 | 0.210 |
Why?
|
| Benchmarking | 1 | 2023 | 146 | 0.190 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 2 | 2021 | 137 | 0.170 |
Why?
|
| Prognosis | 5 | 2024 | 5074 | 0.160 |
Why?
|
| Receptors, Glucocorticoid | 1 | 2020 | 128 | 0.160 |
Why?
|
| Tumor Microenvironment | 2 | 2021 | 691 | 0.160 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2020 | 76 | 0.160 |
Why?
|
| Hemangiosarcoma | 1 | 2019 | 47 | 0.160 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2020 | 1313 | 0.110 |
Why?
|
| Exosomes | 1 | 2014 | 56 | 0.110 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2017 | 267 | 0.110 |
Why?
|
| Pandemics | 1 | 2021 | 1189 | 0.100 |
Why?
|
| Naphthoquinones | 1 | 2012 | 9 | 0.100 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2020 | 2120 | 0.100 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2023 | 1349 | 0.090 |
Why?
|
| Female | 13 | 2024 | 71455 | 0.090 |
Why?
|
| Autophagy | 1 | 2014 | 423 | 0.090 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2014 | 619 | 0.090 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2012 | 219 | 0.080 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2012 | 644 | 0.080 |
Why?
|
| Genetic Counseling | 2 | 2021 | 244 | 0.070 |
Why?
|
| Humans | 15 | 2024 | 133390 | 0.070 |
Why?
|
| Biomarkers, Tumor | 3 | 2023 | 1717 | 0.070 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2019 | 401 | 0.070 |
Why?
|
| Cell Line, Tumor | 3 | 2020 | 3751 | 0.060 |
Why?
|
| Genetic Testing | 2 | 2021 | 1094 | 0.050 |
Why?
|
| Gene Expression | 2 | 2020 | 1614 | 0.050 |
Why?
|
| Everolimus | 1 | 2023 | 50 | 0.050 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2022 | 67 | 0.050 |
Why?
|
| Tissue Distribution | 1 | 2023 | 400 | 0.050 |
Why?
|
| Rural Population | 1 | 2024 | 282 | 0.050 |
Why?
|
| Diarrhea | 1 | 2023 | 341 | 0.050 |
Why?
|
| Middle Aged | 4 | 2024 | 29208 | 0.040 |
Why?
|
| Genes, BRCA2 | 1 | 2021 | 49 | 0.040 |
Why?
|
| Genes, BRCA1 | 1 | 2021 | 61 | 0.040 |
Why?
|
| Penetrance | 1 | 2020 | 111 | 0.040 |
Why?
|
| Mastectomy | 1 | 2019 | 81 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2021 | 3480 | 0.040 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2019 | 168 | 0.040 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2020 | 248 | 0.040 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2021 | 445 | 0.040 |
Why?
|
| Mutation | 2 | 2023 | 6290 | 0.040 |
Why?
|
| Aged | 3 | 2024 | 21605 | 0.040 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2022 | 610 | 0.040 |
Why?
|
| Socioeconomic Factors | 1 | 2021 | 920 | 0.040 |
Why?
|
| Glucocorticoids | 1 | 2020 | 401 | 0.030 |
Why?
|
| Disease Progression | 1 | 2023 | 2237 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 1 | 2023 | 1068 | 0.030 |
Why?
|
| Receptors, Estrogen | 1 | 2020 | 828 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2020 | 844 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2019 | 1596 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2017 | 667 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2017 | 971 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2024 | 5455 | 0.030 |
Why?
|
| Autophagy-Related Protein 7 | 1 | 2014 | 13 | 0.030 |
Why?
|
| Beclin-1 | 1 | 2014 | 29 | 0.030 |
Why?
|
| Ubiquitin-Activating Enzymes | 1 | 2014 | 23 | 0.030 |
Why?
|
| Deoxycytidine | 1 | 2014 | 84 | 0.030 |
Why?
|
| Biological Transport | 1 | 2014 | 369 | 0.030 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2014 | 168 | 0.030 |
Why?
|
| Estrogen Receptor alpha | 1 | 2017 | 474 | 0.030 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2014 | 197 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2024 | 6570 | 0.030 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2014 | 197 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 1484 | 0.030 |
Why?
|
| Biomarkers | 1 | 2023 | 3424 | 0.030 |
Why?
|
| Receptors, Progesterone | 1 | 2017 | 897 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2017 | 1384 | 0.030 |
Why?
|
| Apoptosis | 1 | 2020 | 1928 | 0.030 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2014 | 197 | 0.030 |
Why?
|
| Time Factors | 1 | 2023 | 6569 | 0.020 |
Why?
|
| Glucose Transporter Type 1 | 1 | 2012 | 26 | 0.020 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2012 | 29 | 0.020 |
Why?
|
| Stress, Physiological | 1 | 2014 | 271 | 0.020 |
Why?
|
| BRCA2 Protein | 1 | 2012 | 52 | 0.020 |
Why?
|
| Ki-67 Antigen | 1 | 2012 | 119 | 0.020 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2012 | 110 | 0.020 |
Why?
|
| Random Allocation | 1 | 2012 | 449 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2012 | 613 | 0.020 |
Why?
|
| Neovascularization, Pathologic | 1 | 2012 | 263 | 0.020 |
Why?
|
| Cisplatin | 1 | 2012 | 287 | 0.020 |
Why?
|
| Adult | 2 | 2024 | 31786 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2014 | 716 | 0.020 |
Why?
|
| Glucose | 1 | 2014 | 923 | 0.020 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2014 | 819 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2012 | 446 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2012 | 1006 | 0.020 |
Why?
|
| United States | 1 | 2024 | 11677 | 0.020 |
Why?
|
| Endothelial Cells | 1 | 2012 | 543 | 0.020 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2012 | 791 | 0.020 |
Why?
|
| Calcium | 1 | 2012 | 1145 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 2014 | 1603 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2012 | 2548 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2012 | 1850 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2019 | 17378 | 0.010 |
Why?
|
| Mice | 1 | 2012 | 18910 | 0.010 |
Why?
|
| Male | 1 | 2021 | 65685 | 0.010 |
Why?
|
| Animals | 1 | 2012 | 36377 | 0.010 |
Why?
|